Skip to main content

French vaccine maker Valneva launches Phase 3 trial of its COVID-19 shot after snubbing EU

Study will compare how immune systems respond to Valneva’s vaccine candidate with the one jointly developed by AstraZeneca and the University of Oxford.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.